Ossianix Email Format
Biotechnology ResearchEngland, United Kingdom2-10 Employees
Ossianix is a small, privately held biotechnology company developing biotherapeutic agents based on VNAR, a single-domain antibody derived from sharks. The VNAR scaffold enables rapid delivery of high-affinity molecules to diverse targets that are challenging for conventional antibodies. It operates as a preclinical company with headquarters in Philadelphia, Pennsylvania, and research facilities in Stevenage, Hertfordshire. Its programs focus on neurological conditions, including neurodegeneration, neuro-oncology, ALS, pain, and botulism. The company has pursued collaborations with major pharmaceutical partners to enable brain delivery, such as a 2018 agreement with Novo Nordisk, and has historical ties to Lundbeck.